newsfilter
← Latest News
Business Wire·

Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or “the Company”) today announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®. This product expands Taro’s capabilities to include specialty products.